The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The expansion in indications comes after the company’s Phase III trial saw the treatment extending survival in patients with ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson ...

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of ...